Vázquez-Sánchez Daniel Antonio, Grillo Sara, Carrera-Salinas Anna, González-Díaz Aida, Cuervo Guillermo, Grau Inmaculada, Camoez Mariana, Martí Sara, Berbel Dàmaris, Tubau Fe, Ardanuy Carmen, Pujol Miquel, Càmara Jordi, Domínguez Mª Ángeles
Department of Microbiology, Hospital Universitari de Bellvitge-IDIBELL, 08907 Barcelona, Spain.
CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28020 Madrid, Spain.
Microorganisms. 2022 Dec 3;10(12):2401. doi: 10.3390/microorganisms10122401.
Methicillin-resistant Staphylococcus aureus bloodstream infections (MRSA-BSI) are a significant cause of mortality. We analysed the evolution of the molecular and clinical epidemiology of MRSA-BSI (n = 784) in adult patients (Barcelona, 1990−2019). Isolates were tested for antimicrobial susceptibility and genotyped (PFGE), and a selection was sequenced (WGS) to characterise the pangenome and mechanisms underlying antimicrobial resistance. Increases in patient age (60 to 71 years), comorbidities (Charlson’s index > 2, 10% to 94%), community-onset healthcare-associated acquisition (9% to 60%), and 30-day mortality (28% to 36%) were observed during the 1990−1995 and 2014−2019 periods. The proportion of catheter-related BSIs fell from 57% to 20%. Current MRSA-BSIs are caused by CC5-IV and an upward trend of CC8-IV and CC22-IV clones. CC5 and CC8 had the lowest core genome proportions. Antimicrobial resistance rates fell, and only ciprofloxacin, tobramycin, and erythromycin remained high (>50%) due to GyrA/GrlA changes, the presence of aminoglycoside-modifying enzymes (AAC(6′)-Ie-APH(2″)-Ia and ANT(4′)-Ia), and mph(C)/msr(A) or erm (C) genes. Two CC22-IV strains showed daptomycin resistance (MprF substitutions). MRSA-BSI has become healthcare-associated, affecting elderly patients with comorbidities and causing high mortality rates. Clonal replacement with CC5-IV and CC8-IV clones resulted in lower antimicrobial resistance rates. The increased frequency of the successful CC22-IV, associated with daptomycin resistance, should be monitored.
耐甲氧西林金黄色葡萄球菌血流感染(MRSA-BSI)是导致死亡的重要原因。我们分析了成年患者(巴塞罗那,1990 - 2019年)中MRSA-BSI(n = 784)的分子和临床流行病学演变。对分离株进行了抗菌药物敏感性测试和基因分型(PFGE),并选择部分进行全基因组测序(WGS)以表征泛基因组和抗菌药物耐药性的潜在机制。在1990 - 1995年和2014 - 2019年期间,观察到患者年龄增加(从60岁到71岁)、合并症(Charlson指数> 2,从10%到94%)、社区获得性医疗保健相关感染(从9%到60%)以及30天死亡率(从28%到36%)。导管相关血流感染的比例从57%降至20%。当前的MRSA-BSI由CC5-IV引起,CC8-IV和CC22-IV克隆呈上升趋势。CC5和CC8的核心基因组比例最低。抗菌药物耐药率下降,由于GyrA/GrlA变化、氨基糖苷类修饰酶(AAC(6′)-Ie-APH(2″)-Ia和ANT(4′)-Ia)的存在以及mph(C)/msr(A)或erm (C)基因,仅环丙沙星、妥布霉素和红霉素的耐药率仍较高(> 50%)。两株CC22-IV菌株表现出对达托霉素耐药(MprF替代)。MRSA-BSI已成为医疗保健相关感染,影响患有合并症的老年患者并导致高死亡率。用CC5-IV和CC8-IV克隆进行克隆替代导致抗菌药物耐药率降低。与达托霉素耐药相关的成功的CC22-IV频率增加应受到监测。